ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Epidemiology and Prevention
Global trends and forecasts of nonalcoholic steatohepatitis causing liver cancer incidence and deaths
Provisionally accepted
- 1Fuyang People’s Hospita, Fuyang, China
- 2Wannan Medical College, Wuhu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
BACKGROUND:Metabolic dysfunction-associated steatotic liver disease (MASLD), particularly its progressive form, nonalcoholic steatohepatitis (NASH), has emerged as a leading cause of hepatocellular carcinoma (HCC). The burden of MASLD is increasing rapidly in parallel with the rising global prevalence of obesity and metabolic syndrome, affecting approximately 30% of the world's population. OBJECTIVE: This study aimed to quantify global trends in NASH-related liver cancer incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021 and to project the future disease burden through 2035. METHODS: Data from the Global Burden of Disease Study 2021, encompassing 204 countries, were utilized to evaluate age-standardized incidence (ASIR), mortality (ASMR), and DALY rates (ASDR) across 21 regions and five Socio-demographic Index (SDI) categories, with stratification by age, sex, and geographical location. Future trends were projected using statistical modeling approaches, while decomposition analysis was employed to identify the key drivers of changes in disease burden. RESULTS: From 1990 to 2021, global ASIR of NASH-related HCC increased by 25% (0.4-0.5 per 100,000), with an EAPC of +3.5% (95% UI: 3.4-3.6). ASMR rose by 150% (0.2-0.5 per 100,000; EAPC +3.2%), and ASDR increased by 20% (9.6-11.5 per 100,000; EAPC +2.9%).Regional disparities: Australasia saw the steepest rise (ASIR +200%, EAPC +7.2%; ASMR +150%, EAPC +6.9%). High-income North America followed (ASIR +160%, EAPC +5.3%).Age/sex differences: Incidence peaked in ages 85–89 (6.31 per 100,000 men; 5.56 per 100,000 women). Men had higher burden , for example, 55–59 years: male ASIR 1.28 vs. female 0.87 per 100,000. but gender gaps narrowed after age 75.Risk drivers: Metabolic factors such as high fasting glucose accounted for 29.7% of deaths in ages 80–84; smoking contributed 11.1% in ages 55–59.Projections: By 2035, ASIR will rise to 0.74 per 100,000 (+7% from 2021), driven by aging, population growth, and epidemiological changes (52% of incidence increase globally). CONCLUSION: NASH-related HCC burden exhibits accelerating global growth, concentrated in high-SDI regions. Prioritizing metabolic management and early screening is critical to mitigate future burden.
Keywords: MASLD, Hepatocellular Carcinoma, Disability-adjusted life years, socio-demographic index, GBD
Received: 08 May 2025; Accepted: 27 Nov 2025.
Copyright: © 2025 Cui, Guan, Song and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Kun Song
Jiangtao Yu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.